Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies

Analytical treatment interruptions (ATIs) aim to assess effects of HIV cure-focused interventions, but poses potential risks. Understanding of ATI acceptability among people living with HIV (PLHIV) and their HIV health care providers (HHP) is limited. Two international online surveys for PLHIV and H...

Full description

Saved in:
Bibliographic Details
Published in:AIDS research and human retroviruses Vol. 36; no. 4; p. 260
Main Authors: Lau, Jillian S Y, Smith, Miranda Z, Allan, Brent, Martinez, Cipriano, Power, Jennifer, Lewin, Sharon R, McMahon, James H
Format: Journal Article
Language:English
Published: United States 01.04.2020
Subjects:
Adult
Aged
Anti-HIV Agents - therapeutic use
CD4 Lymphocyte Count
Drug Monitoring
Female
Health Personnel
HIV Infections - drug therapy
HIV Infections - virology
Humans
Male
Middle Aged
Risk Factors
Surveys and Questionnaires
Viral Load
Viremia - diagnosis
Withholding Treatment
Young Adult
clinical trial
analytical treatment interruption
monitoring
HIV cure
social survey
ISSN:1931-8405, 1931-8405
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Analytical treatment interruptions (ATIs) aim to assess effects of HIV cure-focused interventions, but poses potential risks. Understanding of ATI acceptability among people living with HIV (PLHIV) and their HIV health care providers (HHP) is limited. Two international online surveys for PLHIV and HHP assessed understanding and acceptability of monitoring strategies during ATI. Survey items included the following: frequency of CD4, viral load (VL) and clinical assessment, CD4 and VL threshold to restart antiretroviral therapy (ART), acceptability of detectable viremia during ATI, and potential risks of ATI. Responses were collected from July 2017 to January 2018, and a descriptive analysis was performed. Responses to questions asked in both surveys were compared by χ test. Four hundred forty-two completed the PLHIV survey: 22% identified as female, 39% older than 50 years of age, and 64% identified as gay/homosexual/lesbian. Ninety-five percent were on ART, of which 83% reported an undetectable VL. The preferred frequency of CD4, VL, and clinical monitoring during ATI was monthly. Thirty-five percent of respondents preferred VL to remain undetectable during ATI and would not accept any sustained period of viremia, compared to 18% of 144 HHP (  < .01). Having previously interrupted ART predicted preference for VL to remain undetectable during ATI (odds ratio 0.6,  = .05). Both clinicians and PLHIV were concerned about HIV transmission during ATI. Our work demonstrates that PLHIV expectations of ATI in cure-focused clinical trials do not align with current practices, with PLHIV less accepting of viremia during ATI and preferring less frequent monitoring. Clear education messages and careful consent processes need to be developed in relationship to ATIs in HIV cure research.
AbstractList Analytical treatment interruptions (ATIs) aim to assess effects of HIV cure-focused interventions, but poses potential risks. Understanding of ATI acceptability among people living with HIV (PLHIV) and their HIV health care providers (HHP) is limited. Two international online surveys for PLHIV and HHP assessed understanding and acceptability of monitoring strategies during ATI. Survey items included the following: frequency of CD4, viral load (VL) and clinical assessment, CD4 and VL threshold to restart antiretroviral therapy (ART), acceptability of detectable viremia during ATI, and potential risks of ATI. Responses were collected from July 2017 to January 2018, and a descriptive analysis was performed. Responses to questions asked in both surveys were compared by χ test. Four hundred forty-two completed the PLHIV survey: 22% identified as female, 39% older than 50 years of age, and 64% identified as gay/homosexual/lesbian. Ninety-five percent were on ART, of which 83% reported an undetectable VL. The preferred frequency of CD4, VL, and clinical monitoring during ATI was monthly. Thirty-five percent of respondents preferred VL to remain undetectable during ATI and would not accept any sustained period of viremia, compared to 18% of 144 HHP (  < .01). Having previously interrupted ART predicted preference for VL to remain undetectable during ATI (odds ratio 0.6,  = .05). Both clinicians and PLHIV were concerned about HIV transmission during ATI. Our work demonstrates that PLHIV expectations of ATI in cure-focused clinical trials do not align with current practices, with PLHIV less accepting of viremia during ATI and preferring less frequent monitoring. Clear education messages and careful consent processes need to be developed in relationship to ATIs in HIV cure research.
Analytical treatment interruptions (ATIs) aim to assess effects of HIV cure-focused interventions, but poses potential risks. Understanding of ATI acceptability among people living with HIV (PLHIV) and their HIV health care providers (HHP) is limited. Two international online surveys for PLHIV and HHP assessed understanding and acceptability of monitoring strategies during ATI. Survey items included the following: frequency of CD4, viral load (VL) and clinical assessment, CD4 and VL threshold to restart antiretroviral therapy (ART), acceptability of detectable viremia during ATI, and potential risks of ATI. Responses were collected from July 2017 to January 2018, and a descriptive analysis was performed. Responses to questions asked in both surveys were compared by χ2 test. Four hundred forty-two completed the PLHIV survey: 22% identified as female, 39% older than 50 years of age, and 64% identified as gay/homosexual/lesbian. Ninety-five percent were on ART, of which 83% reported an undetectable VL. The preferred frequency of CD4, VL, and clinical monitoring during ATI was monthly. Thirty-five percent of respondents preferred VL to remain undetectable during ATI and would not accept any sustained period of viremia, compared to 18% of 144 HHP (p < .01). Having previously interrupted ART predicted preference for VL to remain undetectable during ATI (odds ratio 0.6, p = .05). Both clinicians and PLHIV were concerned about HIV transmission during ATI. Our work demonstrates that PLHIV expectations of ATI in cure-focused clinical trials do not align with current practices, with PLHIV less accepting of viremia during ATI and preferring less frequent monitoring. Clear education messages and careful consent processes need to be developed in relationship to ATIs in HIV cure research.Analytical treatment interruptions (ATIs) aim to assess effects of HIV cure-focused interventions, but poses potential risks. Understanding of ATI acceptability among people living with HIV (PLHIV) and their HIV health care providers (HHP) is limited. Two international online surveys for PLHIV and HHP assessed understanding and acceptability of monitoring strategies during ATI. Survey items included the following: frequency of CD4, viral load (VL) and clinical assessment, CD4 and VL threshold to restart antiretroviral therapy (ART), acceptability of detectable viremia during ATI, and potential risks of ATI. Responses were collected from July 2017 to January 2018, and a descriptive analysis was performed. Responses to questions asked in both surveys were compared by χ2 test. Four hundred forty-two completed the PLHIV survey: 22% identified as female, 39% older than 50 years of age, and 64% identified as gay/homosexual/lesbian. Ninety-five percent were on ART, of which 83% reported an undetectable VL. The preferred frequency of CD4, VL, and clinical monitoring during ATI was monthly. Thirty-five percent of respondents preferred VL to remain undetectable during ATI and would not accept any sustained period of viremia, compared to 18% of 144 HHP (p < .01). Having previously interrupted ART predicted preference for VL to remain undetectable during ATI (odds ratio 0.6, p = .05). Both clinicians and PLHIV were concerned about HIV transmission during ATI. Our work demonstrates that PLHIV expectations of ATI in cure-focused clinical trials do not align with current practices, with PLHIV less accepting of viremia during ATI and preferring less frequent monitoring. Clear education messages and careful consent processes need to be developed in relationship to ATIs in HIV cure research.
Author Power, Jennifer
Martinez, Cipriano
Smith, Miranda Z
McMahon, James H
Lewin, Sharon R
Lau, Jillian S Y
Allan, Brent
Author_xml – sequence: 1
  givenname: Jillian S Y
  surname: Lau
  fullname: Lau, Jillian S Y
  organization: Infectious Diseases Unit, Alfred Hospital and Monash University, Melbourne, Australia
– sequence: 2
  givenname: Miranda Z
  surname: Smith
  fullname: Smith, Miranda Z
  organization: The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia
– sequence: 3
  givenname: Brent
  surname: Allan
  fullname: Allan, Brent
  organization: International Council of AIDS Service Organizations, Ontario, Canada
– sequence: 4
  givenname: Cipriano
  surname: Martinez
  fullname: Martinez, Cipriano
  organization: National Association of People Living with HIV Australia, Sydney, Australia
– sequence: 5
  givenname: Jennifer
  surname: Power
  fullname: Power, Jennifer
  organization: Australian Research Centre for Sex Health and Society, La Trobe University, Melbourne, Australia
– sequence: 6
  givenname: Sharon R
  surname: Lewin
  fullname: Lewin, Sharon R
  organization: The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Melbourne, Australia
– sequence: 7
  givenname: James H
  surname: McMahon
  fullname: McMahon, James H
  organization: Infectious Diseases Unit, Alfred Hospital and Monash University, Melbourne, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31608648$$D View this record in MEDLINE/PubMed
BookMark eNpNkMFKAzEQhoNUrK0evUqOXrYmm-w2eyzV2kLBgtXrkiazNrJN1iRb6aP4tq5awdMMH_83A_8A9ayzgNAVJSNKRHE7WdyNUkKLEaFUnKBzWjCaCE6y3r-9jwYhvBFCijTNzlCf0ZyInItz9LkCHxpQ0ewhYGfxxMr6EI2SNV57kHEHNuKFjeB920TjbMDG4hW4pga8NHtjX_GHiVs8X7xgaTVeb8F4PAdZd3AqPeCVd3ujuz_fZtx2WpcLSjaAXfXjTVsPycypNoDGT7HVBsIFOq1kHeDyOIfoeXa_ns6T5ePDYjpZJopnJCZFValUbMYaMiIp5UzxSuXQUcg7JnguNcuA5SlozSFnhKlMCMZkNd4ApekQ3fzebbx7byHEcmeCgrqWFlwbypSRjI-zfMy76PUx2m52oMvGm530h_KvzvQLv4B6og
CitedBy_id crossref_primary_10_1089_aid_2021_0170
crossref_primary_10_1089_aid_2021_0192
crossref_primary_10_1371_journal_ppat_1012135
crossref_primary_10_1097_COH_0000000000000771
crossref_primary_10_3390_jpm12020231
crossref_primary_10_1016_S0140_6736_20_30264_6
crossref_primary_10_1093_cid_ciae235
crossref_primary_10_1093_inthealth_ihaa060
crossref_primary_10_1089_apc_2024_0254
crossref_primary_10_1186_s12910_025_01253_x
crossref_primary_10_1093_inthealth_ihaa067
crossref_primary_10_1007_s10461_023_04095_z
crossref_primary_10_1002_jia2_26349
crossref_primary_10_1007_s10461_021_03504_5
crossref_primary_10_1097_COH_0000000000000955
crossref_primary_10_1097_COH_0000000000000973
crossref_primary_10_1016_S1473_3099_23_00267_0
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1089/AID.2019.0118
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1931-8405
ExternalDocumentID 31608648
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: UM1 AI126611
GroupedDBID ---
-~X
.55
.GJ
0R~
1CY
23M
34G
39C
4.4
53G
5GY
5RE
6J9
ABBKN
ABJNI
ACGFO
ACGFS
ACPRK
ADBBV
AENEX
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BNQNF
CAG
CGR
COF
CS3
CUY
CVF
EBS
ECM
EIF
EJD
F5P
IAO
IH2
IHR
IM4
INH
INR
ITC
L7B
MV1
N8Y
NPM
NQHIM
O9-
P2P
RIG
RML
RMSOB
UAP
UE5
X7M
ZGI
7X8
SCNPE
ID FETCH-LOGICAL-c450t-9ffc28b7de50a1143c4fc6effce6de5846ad35e362edd4e6303c58833af7be112
IEDL.DBID 7X8
ISICitedReferencesCount 39
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000500491600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1931-8405
IngestDate Tue Aug 05 11:31:08 EDT 2025
Thu Apr 03 07:08:59 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords clinical trial
analytical treatment interruption
monitoring
HIV cure
social survey
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c450t-9ffc28b7de50a1143c4fc6effce6de5846ad35e362edd4e6303c58833af7be112
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/7185349
PMID 31608648
PQID 2305475674
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2305475674
pubmed_primary_31608648
PublicationCentury 2000
PublicationDate 2020-04-00
20200401
PublicationDateYYYYMMDD 2020-04-01
PublicationDate_xml – month: 04
  year: 2020
  text: 2020-04-00
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle AIDS research and human retroviruses
PublicationTitleAlternate AIDS Res Hum Retroviruses
PublicationYear 2020
SSID ssj0009225
Score 2.4476776
SecondaryResourceType review_article
Snippet Analytical treatment interruptions (ATIs) aim to assess effects of HIV cure-focused interventions, but poses potential risks. Understanding of ATI...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 260
SubjectTerms Adult
Aged
Anti-HIV Agents - therapeutic use
CD4 Lymphocyte Count
Drug Monitoring
Female
Health Personnel
HIV Infections - drug therapy
HIV Infections - virology
Humans
Male
Middle Aged
Risk Factors
Surveys and Questionnaires
Viral Load
Viremia - diagnosis
Withholding Treatment
Young Adult
Title Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies
URI https://www.ncbi.nlm.nih.gov/pubmed/31608648
https://www.proquest.com/docview/2305475674
Volume 36
WOSCitedRecordID wos000500491600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La8MwDDZ7MXbZ-_1Ag129pakdJ6dRtpUV2pJDV3orqWNDL0nXtPsv-7eTHJeeBoNdcjAYgqNYn6Tvkxh7sGEg0bEbLlWmuEDQyzMlJcePHQQ6RhfluDnDrur349EoSX3CrfK0ytWd6C7qvNSUI39CqCyFkpESz7NPTlOjqLrqR2hssu0mQhmyajVadwtPQjd0FTFKg2MgI32PzSBOnlqdV-J1JY-kvPwdXTov0z747_sdsn2PL6FVG8QR2zDFMdvt-Qr6CftO1-rKCsoCXFcSl9CGwYp0Di5POF_WhBeYFpA6ojl0p5R_AErewntnCFmRw4BKDVDLmYDkTJB6dZ_biQATuqQnJqYVlNbte1nODW-XelmZHDyV8ZR9tN8GL-_cj2fgWshgwRNrdRhPVG5kkGFY1dTC6sjgqolwDYFNlqMVoIc0eS5MhM5SS5ptnFk1MYjzzthWURbmggHCRpGjzSRRkpG0FzFMc6IEDWOfWCvFJbtfHfoYzZ9qGllhymU1Xh_7JTuvv9x4VvfpGDcbEQZsIr76w-5rthdSJO04OTds2-LPb27Zjv5aTKv5nbMrfPbT3g-LJNdh
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Perspectives+on+Analytical+Treatment+Interruptions+in+People+Living+with+HIV+and+Their+Health+Care+Providers+in+the+Landscape+of+HIV+Cure-Focused+Studies&rft.jtitle=AIDS+research+and+human+retroviruses&rft.au=Lau%2C+Jillian+S+Y&rft.au=Smith%2C+Miranda+Z&rft.au=Allan%2C+Brent&rft.au=Martinez%2C+Cipriano&rft.date=2020-04-01&rft.eissn=1931-8405&rft.volume=36&rft.issue=4&rft.spage=260&rft_id=info:doi/10.1089%2FAID.2019.0118&rft_id=info%3Apmid%2F31608648&rft_id=info%3Apmid%2F31608648&rft.externalDocID=31608648
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1931-8405&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1931-8405&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1931-8405&client=summon